This site is intended for US healthcare professionals only. Visit Patient Site

RUTH IS A 75-YEAR-OLD LONG-TERM CARE (LTC) RESIDENT STRUGGLING WITH UNTREATED OVERACTIVE BLADDER (OAB)

Impact of untreated OAB symptoms on Ruth's daily activities in the last 3+ months

Leakage episodes and skin irritation due to prolonged leakage exposure despite daily briefing
Frequent nighttime falls trying to get to the restroom
Family concerns about more frequent urinary tract infections and sacral wounds
Dysphagia impacts her ability to swallow medications
Unable to identify and report OAB symptoms due to dementia

Not an actual patient.

Comorbidities

Prediabetes
Hypertension
Dyslipidemia
Back pain

Osteoporosis
Depression
Atrial fibrillation
Gastroesophageal reflux disease (GERD)

Current medications

Metformin
Lisinopril
Simvastatin
Omeprazole
Alendronate

Venlafaxine
Metoprolol
Apixaban
Tramadol

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

GEMTESA is contraindicated in patients with known hypersensitivity to vibegron or any components of GEMTESA. Hypersensitivity reactions, such as angioedema, have occurred.

WARNINGS AND PRECAUTIONS

Urinary Retention

Urinary retention has been reported in patients taking GEMTESA. The risk of urinary retention may be increased in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for the treatment of OAB. Monitor patients for signs and symptoms of urinary retention, particularly in patients with bladder outlet obstruction and patients taking muscarinic antagonist medications for the treatment of OAB. Discontinue GEMTESA in patients who develop urinary retention.

Angioedema

Angioedema of the face and/or larynx has been reported with GEMTESA. Angioedema has been reported to occur hours after the first dose or after multiple doses. Angioedema, associated with upper airway swelling, may be life-threatening. If involvement of the tongue, hypopharynx, or larynx occurs, immediately discontinue GEMTESA and provide appropriate therapy and/or measures necessary to ensure a patent airway.

ADVERSE REACTIONS

Most common adverse reactions (≥2%) reported with GEMTESA were headache, urinary tract infection, nasopharyngitis, diarrhea, nausea, and upper respiratory tract infection.

INDICATIONS AND USAGE

GEMTESA^® is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.